Form 4: CalciMedica Chief Scientific Officer Acquires Stock Options
SEC Form 4 Filing
Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., reports the acquisition of employee stock options.
Summary
- Kenneth A. Stauderman, the Chief Scientific Officer of CalciMedica, Inc., filed a Form 4 to report changes in beneficial ownership.
- The reported transaction involves the acquisition of 62,500 employee stock options with an exercise price of $4.16.
- These options vest in equal monthly installments over a four-year period following March 28, 2024, with an expiration date of August 26, 2034.
- Following the reported transaction, Stauderman directly owns 62,500 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants. The acquisition of options by an executive is generally viewed as a slightly positive sign, indicating confidence in the company's future.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.
Stakeholder Impact
- The acquisition of stock options by a key executive could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/28/2024 | Start date for monthly vesting of stock options over a four-year period. |
| 08/27/2024 | Date of the transaction: acquisition of employee stock options. |
| 08/28/2024 | Date of signature on the Form 4 filing. |
| 08/26/2034 | Expiration date of the acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.